Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Loncastuximab Tesirine Shows Synergistic Activity With Ibrutinib in DLBCL, MCL

June 24th 2020

The combination of the antibody-drug conjugate loncastuximab tesirine and ibrutinib showed early clinical activity with manageable toxicity in patients with relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma.

FDA Lifts Partial Clinical Hold on TELLOMAK Trial With Lacutamab in Advanced T-Cell Lymphomas

June 24th 2020

The FDA has lifted a partial clinical hold that had been placed on the phase 2 TELLOMAK trial, which is examining the safety and efficacy of lacutamab in patients with advanced T-cell lymphoma.

Axi-Cel Elicits Encouraging Activity in Indolent Follicular Lymphoma, Marginal Zone Lymphoma

June 24th 2020

Caron Jacobson, MD, discusses the initial ZUMA-5 findings and the next steps with axicabtagene ciloleucel in follicular lymphoma and marginal zone lymphoma.

Dr. Kuruvilla on the Broad Utility of Pembrolizumab in Hodgkin Lymphoma

June 24th 2020

John Kuruvilla, MD, FRCPC, discusses the broad utility of pembrolizumab in Hodgkin lymphoma.

Dr. Hill on the Safety Profile of Selinexor in Relapsed/Refractory DLBCL

June 24th 2020

Brian T. Hill, MD, PhD, discusses the safety profile of selinexor in relapsed/refractory diffuse large B-cell lymphoma.

Axi-Cel Retreatment Demonstrates Clinical Efficacy in Large B-Cell Lymphoma

June 24th 2020

Findings from an exploratory analysis of the phase 1/2 ZUMA-1 trial demonstrated clinical efficacy in patients with relapsed/refractory large B-cell lymphoma who were retreated with the CAR T-cell therapy axicabtagene ciloleucel.

Expanded FDA Label Sought for Ibrutinib/Rituximab With Long-Term Data in Waldenström Macroglobulinemia

June 23rd 2020

A supplemental new drug application has been submitted to the FDA for review for the use of ibrutinib in combination with rituximab as a treatment for patients with Waldenström macroglobulinemia.

Suggested Benefit of Novel BTK Inhibitor Observed in MCL Models and in NHL Combo Regimen

June 23rd 2020

In preclinical models, the novel irreversible BTK inhibitor TG-1701 demonstrated similar activity to ibrutinib in mantle cell lymphoma cell lines and showed additive benefit when combined with ublituximab and umbralisib in non-Hodgkin lymphoma model.

Dr. Furman on FDA-Approved BTK Inhibitors in B-Cell Malignancies

June 23rd 2020

Richard R. Furman, MD, discusses FDA-approved BTK inhibitors in B-cell malignancies.

Dr. Goldberg on Financial Toxicities Faced in Hematology

June 23rd 2020

Stuart L. Goldberg, MD, discusses financial toxicities faced in hematology.

FDA Schedules ODAC Meeting on Belantamab Mafodotin in Relapsed/Refractory Myeloma

June 22nd 2020

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for July 14, 2020, to discuss data supporting a biologics license application for belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma who have previously received at least 4 prior therapies.

Dr. Hill on the FDA Approval of Selinexor in DLBCL

June 22nd 2020

Brian T. Hill, MD, PhD, discusses the FDA approval of selinexor (Xpovio) in diffuse large B-cell lymphoma (DLBCL).

FDA Approves Selinexor for Relapsed/Refractory DLBCL

June 22nd 2020

The FDA has approved selinexor for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.

Dr. Ramakrishnan on the Promise of Biosimilars in Hematology

June 22nd 2020

Praveen Ramakrishnan, MD, discusses the promise of biosimilars in hematology.

Hispanic Patients With Select Blood Cancers Have Worse Survival Outcomes

June 22nd 2020

Significant differences were seen between Hispanic and non-Hispanic white patients with hematological malignancies in Texas in terms of the age of diagnosis and long-term survival outcomes.

Dr. Talati on the Rationale for Venetoclax in AML

June 19th 2020

Chetasi Talati, MD, discusses the rationale for investigating venetoclax in acute myeloid leukemia.

Dr. Dimopoulos on the Utility of Zanubrutinib in Waldenström Macroglobulinemia

June 19th 2020

Meletios A. Dimopoulos, MD, discusses the utility of zanubrutinib (Brukinsa) in Waldenström macroglobulinemia.

Dr. Kuruvilla on the Treatment Landscape in Relapsed/Refractory Hodgkin Lymphoma

June 19th 2020

John Kuruvilla, MD, FRCPC, discusses the treatment landscape in relapsed/refractory Hodgkin lymphoma.

Lead Investigator Highlights Pembrolizumab Activity in Relapsed/Refractory Hodgkin Lymphoma

June 19th 2020

John Kuruvilla, MD, FRCPC, discusses the pivotal KEYNOTE-204 findings in Hodgkin lymphoma and the future of checkpoint inhibitors.

EMA Accepts Application for Zanubrutinib in Waldenström Macroglobulinemia

June 19th 2020

The European Medicines Agency has validated and accepted a marketing authorization application for zanubrutinib for the treatment of patients with Waldenström macroglobulinemia who have received at least 1 prior therapy or as frontline treatment for patients who are ineligible for chemoimmunotherapy.